Targeting a brain receptor to help reduce opioid cravings

Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probes

NIH-funded research University of Minnesota · NIH-11190963

This study is looking at new medications that can help people with opioid use disorder by targeting a specific brain receptor to reduce cravings and prevent relapse, all while aiming to avoid side effects.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Minnesota NIH-funded
Lab location1 site (Minneapolis, United States)
Project IDNIH-11190963 on NIH RePORTER

What this research studies

This research focuses on developing new small molecules that target the neurotensin receptor 1 (NTSR1) in the brain to help individuals with opioid use disorder (OUD) manage their cravings and reduce the risk of relapse. The approach involves creating biased allosteric modulators that can influence brain signaling without causing unwanted side effects. By understanding how NTSR1 interacts with dopamine pathways, the research aims to provide a safer treatment option for those struggling with opioid addiction.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking new treatment options.

Not a fit: Patients who do not have opioid use disorder or those who are not actively seeking treatment for addiction may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that significantly reduce opioid cravings and improve recovery outcomes for patients with opioid use disorder.

How similar studies have performed: Previous research has shown promise in targeting neurotensin receptors for addiction treatment, indicating potential success for this novel approach.

Where this research is happening

Minneapolis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions addictive disorder
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.